Arecor's Tetris launches 'Ogluo' in Austria

Biopharmaceutical company Arecor Therapeutics announced on Wednesday that its subsidiary Tetris Pharma has launched ‘Ogluo’, or glucagon prefilled autoinjector pens, as a treatment for severe hypoglycaemia in children and adults living with diabetes in Austria.

The AIM-traded firm said it was the second Europe launch in the Ogluo European roll-out strategy.

It described Ogluo as a ready-to-use, ambiently stored preparation of glucagon to treat severe hypoglycemia for people living with diabetes.

There were an estimated 450,000 adults living with diabetes in Austria, it added.

Pricing for Ogluo had been published in the ‘Warenverzeichnis’ - the reference for all Austrian pharmacies, insurers and wholesalers - managed by the Apotheker-Verlages.

Arecor and Tetris said the launch built on the roll-out of Ogluo in Germany and Britain as part of its pan-Europe commercialisation programme, through which Tetris intended to commercialise Ogluo in “core” European markets.

The company was currently in discussions with various health authorities across Europe to ensure timely launches in additional major European countries.

“In Austria, people living with diabetes will now be able to receive Ogluo to tackle severe hypoglycemic events, enabling patients and those around them to act quickly when such an event happens,” said Tetris managing director Dr Shafiq Choudhary.

“With this launch in Austria, we look forward to expanding our reach within Europe over the coming months to bring this new treatment to people living with diabetes.”

At 1113 GMT, shares in Arecor Therapeutics were up 4.17% at 250p.

Reporting by Josh White for Sharecast.com.